CAPTRUST Financial Advisors’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $87.4M | Buy |
3,628,237
+142,789
| +4% | +$3.74M | 0.13% | 133 |
|
|
2026
Q1 | $97.9M | Buy |
3,485,448
+207,374
| +6% | +$5.52M | 0.17% | 116 |
|
|
2025
Q4 | $81.6M | Sell |
3,278,074
-959,273
| -23% | -$24.2M | 0.16% | 123 |
|
|
2025
Q3 | $108M | Sell |
4,237,347
-37,089
| -0.9% | -$915K | 0.22% | 89 |
|
|
2025
Q2 | $104M | Sell |
4,274,436
-1,942,385
| -31% | -$45.3M | 0.23% | 85 |
|
|
2025
Q1 | $158M | Buy |
6,216,821
+4,803,202
| +340% | +$126M | 0.4% | 49 |
|
|
2024
Q4 | $37.5M | Buy |
1,413,619
+1,112
| +0.1% | +$30.2K | 0.11% | 157 |
|
|
2024
Q3 | $40.9M | Sell |
1,412,507
-35,457
| -2% | -$1.03M | 0.12% | 148 |
|
|
2024
Q2 | $40.5M | Sell |
1,447,964
-61,520
| -4% | -$1.69M | 0.13% | 137 |
|
|
2024
Q1 | $41.9M | Sell |
1,509,484
-452,947
| -23% | -$12.6M | 0.15% | 132 |
|
|
2023
Q4 | $56.5M | Sell |
1,962,431
-734,093
| -27% | -$22.2M | 0.19% | 108 |
|
|
2023
Q3 | $89.4M | Buy |
2,696,524
+171,973
| +7% | +$6.08M | 0.34% | 63 |
|
|
2023
Q2 | $92.6M | Buy |
2,524,551
+945,396
| +60% | +$36.8M | 0.37% | 60 |
|
|
2023
Q1 | $64.4M | Buy |
1,579,155
+45,404
| +3% | +$1.96M | 0.28% | 83 |
|
|
2022
Q4 | $78.6M | Buy |
1,533,751
+78,024
| +5% | +$3.74M | 0.4% | 54 |
|
|
2022
Q3 | $63.7M | Buy |
1,455,727
+155,373
| +12% | +$7.55M | 0.37% | 61 |
|
|
2022
Q2 | $68.2M | Buy |
1,300,354
+110,438
| +9% | +$5.63M | 0.44% | 46 |
|
|
2022
Q1 | $61.6M | Buy |
1,189,916
+171,622
| +17% | +$8.9M | 0.4% | 54 |
|
|
2021
Q4 | $60.1M | Buy |
1,018,294
+105,796
| +12% | +$5.24M | 0.41% | 53 |
|
|
2021
Q3 | $39.2M | Buy |
912,498
+138,290
| +18% | +$6.13M | 0.33% | 75 |
|
|
2021
Q2 | $30.3M | Buy |
774,208
+10,936
| +1% | +$425K | 0.28% | 87 |
|
|
2021
Q1 | $27.7M | Buy |
763,272
+86,612
| +13% | +$3.08M | 0.3% | 82 |
|
|
2020
Q4 | $24.9M | Buy |
676,660
+3,439
| +0.5% | +$126K | 0.33% | 78 |
|
|
2020
Q3 | $23.2M | Sell |
673,221
-50,677
| -7% | -$1.78M | 0.39% | 59 |
|
|
2020
Q2 | $23.2M | Buy |
723,898
+47,489
| +7% | +$1.61M | 0.38% | 70 |
|
|
2020
Q1 | $20.4M | Sell |
676,409
-43,904
| -6% | -$1.5M | 0.45% | 55 |
|
|
2019
Q4 | $26.7M | Buy |
720,313
+213,920
| +42% | +$7.62M | 0.42% | 63 |
|
|
2019
Q3 | $17.3M | Buy |
506,393
+22,299
| +5% | +$811K | 0.61% | 34 |
|
|
2019
Q2 | $19.9M | Buy |
484,094
+72,243
| +18% | +$2.87M | 0.74% | 28 |
|
|
2019
Q1 | $16.6M | Buy |
411,851
+63,127
| +18% | +$2.53M | 0.67% | 27 |
|
|
2018
Q4 | $14.4M | Sell |
348,724
-19,386
| -5% | -$805K | 0.77% | 23 |
|
|
2018
Q3 | $15.4M | Buy |
368,110
+102,608
| +39% | +$3.95M | 0.69% | 26 |
|
|
2018
Q2 | $9.14M | Buy |
265,502
+12,892
| +5% | +$441K | 0.51% | 34 |
|
|
2018
Q1 | $8.4M | Sell |
252,610
-8,444
| -3% | -$290K | 0.52% | 30 |
|
|
2017
Q4 | $8.97M | Buy |
261,054
+102,323
| +64% | +$3.49M | 0.54% | 32 |
|
|
2017
Q3 | $5.26M | Buy |
158,731
+132,287
| +500% | +$4.25M | 0.4% | 45 |
|
|
2017
Q2 | $843K | Buy |
+26,444
| New | +$834K | 0.11% | 77 |
|
Other funds holding PFE
CAPTRUST Financial Advisors's PFE Position: Q2 2026 in Review
CAPTRUST Financial Advisors increased its Pfizer (PFE) stake by 4.1% in Q2 2026, buying an estimated $3.74M and bringing the position to 3,628,237 shares worth $87.4M. The position accounts for 0.13% of the portfolio, ranked #133.
CAPTRUST Financial Advisors first reported a position in PFE in Q2 2017 and has held it in 37 quarters since. The position peaked at $158M in Q1 2025. 2,818 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- CAPTRUST Financial Advisors held 3,628,237 shares of Pfizer worth $87.4M as of Q2 2026.
- CAPTRUST Financial Advisors bought 142,789 Pfizer shares in Q2 2026, an estimated $3.74M.
- Pfizer made up 0.13% of CAPTRUST Financial Advisors's portfolio in Q2 2026, its #133 holding.
- CAPTRUST Financial Advisors first reported a position in Pfizer in Q2 2017 and has held it in 37 quarters since.
- CAPTRUST Financial Advisors's Pfizer position peaked at $158M in Q1 2025.
- 2,818 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on CAPTRUST Financial Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.